Generic Name and Formulations:
Fosphenytoin sodium (prodrug of phenytoin) 75mg/mL (equivalent to 50mg/mL phenytoin sodium); soln for IV or IM inj.
Indications for CEREBYX:
Control of generalized tonic-clonic status epilepticus. Seizure prophylaxis and treatment in neurosurgery. Short-term substitution for oral phenytoin. Use only when oral phenytoin administration is not possible.
Must prescribe and dispense fosphenytoin sodium inj doses, infusion rates and concentration in dosing solutions expressed as phenytoin sodium equivalents (PE); see full labeling. Max infusion rate: 150mg PE/min. Status epilepticus: loading dose: 15–20mg PE/kg IV administered at 100–150mg PE/min; nonemergent loading dose: 10–20mg PE/kg IV or IM inj; maintenance dose: initially 4–6mg PE/kg/day. Substitution for oral phenytoin: give same total daily dose by IM or IV.
Sinus bradycardia, sinoatrial block, or 2nd and 3rd degree A-V block. Adams-Stokes syndrome. Concomitant delavirdine.
Increased risk of SJS/TEN if HLA-B*1502 positive (esp. in Asians); avoid as an alternative for carbamazepine. Do not make adjustments in recommended doses when substituting fosphenytoin sodium injection for phenytoin sodium or vice versa. Hypotension and severe myocardial insufficiency; monitor cardiac function during and after administration; reduce or discontinue drug if needed. Hepatic or renal impairment. Phosphate restricted. Hypoalbuminemia. Porphyria. Diabetes. Monitor respiratory function during therapy; and phenytoin serum levels upon complete conversion to phenytoin (approx. 2hrs after IV or 4hrs after IM). Adjust dose gradually. Avoid abrupt cessation. Alcoholics. Slow metabolizers. Elderly (use lower dose). Debilitated. Pregnancy (Cat.D; see full labeling). Nursing mothers: not recommended.
Potentiated by acute alcohol intake, amiodarone, antiepileptics, azoles, capecitabine, chloramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, fluvoxamine, methylphenidate, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone. Antagonized by chronic alcohol abuse, carbamazepine, reserpine, bleomycin, carboplatin, cisplatin, doxorubicin, methotrexate, ritonavir, St. John's wort, theophylline, vigabatrin. Antagonize azoles, corticosteroids, coumarin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D, HIV antivirals (eg, amprenavir, efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir), antiepileptics, atorvastatin, others. Variable effects with phenobarbital, valproic acid, and sodium valproate. Concomitant tricyclic antidepressants may precipitate seizures. Concomitant fosamprenavir/ritonavir may potentiate amprenavir. Variable PT/INR responses with concomitant warfarin. Concomitant neuromuscular blockers (eg, pancuronium, vecuronium, rocuronium, cisatracurium); may need higher infusion rate. Caution with drugs that are highly bound to serum albumin. May decrease T4 serum concentrations, or produce low results in dexamethasone or metyrapone tests. May increase serum concentrations of glucose, alkaline phosphatase and gamma glutamyl transpeptidase.
Nystagmus, dizziness, pruritus, paresthesia, headache, somnolence, ataxia, tinnitus, nausea, cardiovascular collapse, CNS depression, hypotension (esp. after high doses or rapid IV), atrial and ventricular conduction depression, ventricular fibrillation, DRESS, multiorgan hypersensitivity, rash (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis; discontinue if occurs), hepatotoxicity (discontinue immediately; do not readminister), blood dyscrasias, lymphadenopathy, hyperglycemia, lowering of serum folate levels, bradycardia, others.
Vials 100mg PE/2mL—1, 25; 500mg PE/10mL—1, 10
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|